HOMOLOGOUS RECOMBINATION DEFICIENCY
Clinical trials for HOMOLOGOUS RECOMBINATION DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new HOMOLOGOUS RECOMBINATION DEFICIENCY trials appear
Sign up with your email to follow new studies for HOMOLOGOUS RECOMBINATION DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Prostate cancer study cancelled before it started
Disease control TerminatedThis study aimed to see if a person's race or ethnicity changed how well a drug combination (niraparib, abiraterone acetate, and prednisone) worked for a certain type of advanced prostate cancer. It planned to enroll Black, Hispanic, White, and Native American men whose cancer ha…
Matched conditions: HOMOLOGOUS RECOMBINATION DEFICIENCY
Phase: PHASE2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated May 26, 2026 05:08 UTC
-
New drug combo targets hard-to-treat cancers in early trial
Disease control OngoingThis early-phase study tests an experimental drug called MOMA-313, given alone or with another drug (olaparib), in people with advanced solid tumors that have a specific DNA repair problem (HR deficiency). The main goals are to check safety, find the best dose, and see if the dru…
Matched conditions: HOMOLOGOUS RECOMBINATION DEFICIENCY
Phase: PHASE1 • Sponsor: MOMA Therapeutics • Aim: Disease control
Last updated May 26, 2026 05:05 UTC
-
Lung cancer clue: could a DNA glitch open door to new treatments?
Knowledge-focused OngoingThis study examines how often a specific DNA repair issue (HRD) occurs in people with a certain type of advanced lung cancer (EGFR-mutated NSCLC). Researchers will analyze tumor samples from 100 participants to see if this issue is linked to how the cancer behaves. The goal is to…
Matched conditions: HOMOLOGOUS RECOMBINATION DEFICIENCY
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated May 26, 2026 05:08 UTC